Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer
Icotinib as Consolidation Therapy After Synchronous or Sequential Chemoradiotherapy in Stage IIIA-IIIB Non-small Cell Lung Cancer With EGFR Sensitive Mutation: A Single Center, Single Arm, Open Label and Prospective Clinical Study
Sponsor: Betta Pharmaceuticals Co., Ltd.
Listed as NCT03396185, this PHASE2 trial focuses on EGFR Gene Mutation and Non Small Cell Lung Cancer Stage IIIA and remains ongoing. Sponsored by Betta Pharmaceuticals Co., Ltd., it has been updated 8 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Mar 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Mar 2023 [monthly]
Recruiting PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Aug 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Betta Pharmaceuticals Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .